Carbobenzoxy-Leu-Leu-leucinal (MG132) is a proteasome inhibitor involved in the degradation of connexin 43 (Cx43), a gap junction protein associated with increased glioma invasiveness. This evidence concerns the gene GJA1 and central nervous system cancer.